ACR Convergence 2026 Archives - ACR Meeting Abstracts

Abstract Number: 2743

E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI) and New-Onset Autoimmune and Inflammatory Disease: A Propensity Score-Matched Cohort Study
Abstract Number: 1781

Earlier CRS Identification with Continuous Wearable Monitoring in Outpatient CAR T‑Cell Therapy
Abstract Number: 1705

Earlier Mortality Burden Among Black Americans With Systemic Sclerosis: Evidence of Accelerated Mortality Across the Lifespan
Abstract Number: 1614

Early and Sustained Improvements in Fatigue and Physical Function with Secukinumab in Patients with Psoriatic Arthritis: A Pooled Analysis of FUTURE Studies
Abstract Number: 2292

Early Anti-TNF Therapy Added to Methotrexate versus Methotrexate Alone in Psoriatic Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 2330

Early axial spondyloarthritis: clinical characteristics and drug survival
Abstract Number: 2197

Early Biologic Therapy in SLE Reduces Hospitalizations, New Organ Involvement, and Corticosteroid Escalation: A Propensity Score Matched Analysis
Abstract Number: 2778

Early Changes in Body Composition, Hydration Status, and Phase Angle During Glucocorticoid Therapy in Rheumatic Diseases Using Bioelectrical Impedance Analysis: A Retrospective Study
Abstract Number: 1262

Early Damage Accrual Following Lupus Nephritis Onset: Patterns and Predictors in Patients Younger Than 50 Years
Abstract Number: 0785

Early Detection and Treatment of Autoimmune Interstitial Lung Disease: A Systematic Review Across Connective Tissue Diseases
Abstract Number: 0980

Early Epithelial Remodeling Precedes Fibrosis in Systemic Sclerosis Gastrointestinal Disease
Abstract Number: 1263

Early Identification of Proteinuria in Lupus: Diagnostic Performance of First Morning, Random, and 24-Hour Urine Protein Measurements
Abstract Number: 2009

Early intervertebral bone formation in recent-onset arthritis revealed by X-ray phase-contrast imaging: evidence for parallel, non-sequential bone and inflammatory processes
Abstract Number: 0898

Early Post-Vaccination Antibody Levels, One-year Follow-up and Breakthrough Herpes Zoster After Recombinant Zoster Vaccination in a Large Autoimmune Rheumatic Diseases Cohort
Abstract Number: 0925

Early Prediction of Work Disability in Systemic Lupus Erythematosus Using Machine Learning: An Early-Warning Model for Functional Decline
Abstract Number: 2198

Early Proteinuria Reduction as a Predictor of Long-Term Renal Outcomes in Lupus Nephritis: A Systematic Review and Meta-Analysis
Abstract Number: 0308

Early proteinuria reduction predicts complete renal response at 12 months in first-episode lupus nephritis
Abstract Number: 0447

Early Suppression of Power Doppler Synovitis After Subcutaneous Methotrexate Initiation in Rheumatoid Arthritis: A Multicentre Real-World Study
Abstract Number: 0918

Early Synovial Immune Landscape Is Associated With 5-years Outcomes In Rheumatoid Arthritis
Abstract Number: 0166

Early Tocilizumab Initiation and 12-Month Hospitalisation in Giant Cell Arteritis: A Propensity Matched Real World Cohort Study
Abstract Number: 2618

Early Tocilizumab Initiation in Adult-onset Still’s Disease: A Nationwide Japanese Retrospective Cohort Study
Abstract Number: 2903

Early Treatment Pathways Improve Outcomes in Severe Autoimmune Diseases: Systematic Review and Evidence Synthesis of 430 Studies
Abstract Number: 0167

Early Use of Sarilumab in Patients with Glucocorticoid-Resistant PMR Improves Outcomes – Insights from Randomized Controlled Trial and Real-World Data
Abstract Number: 1128

Early Versus Delayed Tocilizumab in Giant Cell Arteritis: Exploring the Window of Opportunity
Abstract Number: 0309

Early Versus Late Anifrolumab Initiation in SLE: Real‑World Effectiveness and Glucocorticoid‑Sparing Outcomes
Abstract Number: 2247

Early versus Late Cardiovascular Events in Systemic Lupus Erythematosus
Abstract Number: 0168

Early-onset Idiopathic Systemic Polyarteritis Nodosa: A Distinct Autoinflammatory-like Phenotype with Refractory Disease Course
Abstract Number: 0724

Echocardiographic Surveillance for Pulmonary Hypertension in Systemic Sclerosis Is Infrequent in Real-World Clinical Practice
Abstract Number: 0844

ECMO in Systemic Rheumatologic Disease: Outcomes from a Multicenter Retrospective Cohort (2016-2025)
Abstract Number: 2575

Ecologic Momentary Assessment Identifies Distinct Post-Operative Trajectories after Total Knee Replacement
Abstract Number: 1743

Economic and Healthcare Utilization Burden of Uncontrolled Versus Controlled Gout in US Claims Data
Abstract Number: 1722

Economic Burden of ANCA-Associated Vasculitis in the United States: A Real-World Claims Analysis
Abstract Number: 0786

Economic Evaluation Models of Specialty Disease-Modifying Anti-Rheumatic Drugs After Failure of Conventional Therapies
Abstract Number: 0547

Educational Online Webinars of European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) for Patients, Caregivers and Healthcare Professionals: the Trajectory from 2019 up to 2025
Abstract Number: 1264

Effect of Air Pollution on Disease Activity in Patients with Systemic Lupus Erythematosus
Abstract Number: 0216

Effect of Aminaphtone on microvascular damage in SSc patients: a nailfold videocapillaroscopy analysis
Abstract Number: 0944

Effect of Exercise Snack Intervention on Cardiorespiratory Fitness, Metabolic and Clinical Outcomes in Idiopathic Inflammatory Myopathies: Interim Analysis of a Randomized Controlled Trial
Abstract Number: 1265

Effect of Hydroxychloroquine Blood Level Monitoring on Medication Adherence in Systemic Lupus Erythematosus: a Systematic Review and Meta-Analysis
Abstract Number: 0448

Effect of Nintedanib Associated to Abatacept in Rheumatoid Arthritis-Associated Interstitial Lung Disease. National Multicenter Study of 526 Patients.
Abstract Number: 2555

Effect of Romosozumab on Bone Metabolism, Lipid Profile, and Laboratory Parameters in Real-World Clinical Practice.
Abstract Number: 2692

Effect of TLC599 on Structural Progression in Osteoarthritis of the Knee: Extension of an Exploratory Analysis of a Phase 3 Randomized, Placebo-Controlled Clinical Trial Using a combined Trial Placebo and Real World Digital Twin Analysis
Abstract Number: 2248

Effective Practices in Using Large Language Model Agents for Diagnostic Support in Systemic Lupus Erythematosus
Abstract Number: 0266

Effectiveness and Safety of Anifrolumab in Non-Systemic Cutaneous Lupus. Multicenter Study of 28 Patients from Clinical Practice
Abstract Number: 2133

Effectiveness and Safety of Avacopan Added to Standard of Care (SOC) Versus SOC Alone in ANCA-associated Vasculitis
Abstract Number: 0169

Effectiveness and safety of biosimilar tocilizumab in patients with giant cell arteritis who previously were receiving the original tocilizumab. Real-world clinical practice
Abstract Number: 0170

Effectiveness and Safety of Janus Kinase Inhibitors in Refractory Takayasu Arteritis: A Multicenter Caucasian Cohort and Systematic Literature Review
Abstract Number: 1744

Effectiveness and Safety of Recombinant Zoster Vaccine in Psoriasis Patients Aged 18 Years and Older
Abstract Number: 2744

Effectiveness and Safety of Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients Aged 18 Years and Older
Abstract Number: 0267

Effectiveness and Safety of Zebeituimab (Anruike) in Active Systemic Lupus Erythematosus: A Real-World Observational Study
Abstract Number: 0358

Effectiveness of Guselkumab vs Golimumab in Participants with Active Psoriatic Arthritis and Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Interim Results at 6 Months in a Phase 3b, Randomized, Open-Label, Pragmatic Trial
Abstract Number: 1665

Effectiveness of latent tuberculosis screening prior to initiation of targeted therapies in patients with autoimmune inflammatory rheumatic disease and vasculitides.
Abstract Number: 2158

Effectiveness of Rituximab in Joint Involvement of Systemic Sclerosis
Abstract Number: 1895

Effectiveness of Sarilumab versus Methotrexate as Glucocorticoid-sparing Therapy in Polymyalgia Rheumatica
Abstract Number: 0765

Effects of a Bias-Reducing Individuation Intervention on Rheumatology Care Quality: Results from a Randomized Controlled Trial
Abstract Number: 0217

Effects of different B cell targeting therapies on microvascular changes in systemic sclerosis
Abstract Number: 2426

Effects of Hydroxychloroquine on coronary atherosclerosis and cardiovascular risk in rheumatoid arthritis
Abstract Number: 0385

Effects of Sex and Race on the Genetic Association of CARD9 S12N on Axial Spondyloarthritis
Abstract Number: 0929

Efficacy and safety of add-on glucocorticoid pulse therapy during remission induction in patients with ANCA-associated vasculitis: a target trial emulation study
Abstract Number: 1376

Efficacy and Safety of B-Cell Targeted Monoclonal Antibodies in Primary Sjögren’s Syndrome: A Systematic Review and Meta-analysis
Abstract Number: 0421

Efficacy and Safety of Baricitinib in Active Sjögren disease: A Multicenter, Randomized, Controlled Trial
Abstract Number: 2199

Efficacy and Safety of Belimumab without Glucocorticoid Use in Systemic Lupus Erythematosus: A Pilot Randomized Double-Blind Placebo-Controlled Trial
Abstract Number: 0268

Efficacy and Safety of Belimumab, Anifrolumab, and Obinutuzumab for Systemic Lupus Erythematosus: A Network Meta-analysis
Abstract Number: 2864

Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis: Results from the Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase II (BEACON) Trial
Abstract Number: 1615

Efficacy and Safety of Darbinurad Combined with Allopurinol in Patients with Gout: A Randomized, Open-Label, Multiple-Dose Phase II Study
Abstract Number: 0269

Efficacy and Safety of Edecesertib (GS-5718) for the Treatment of Cutaneous Lupus Erythematosus: Results From a Ph2a Study
Abstract Number: 1616

Efficacy and Safety of Emapalumab in Adults with Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials
Abstract Number: 1881

Efficacy and safety of goflikicept, an IL-1β and IL-1α inhibitor, in familial Mediterranean fever: an international randomized clinical trial
Abstract Number: 1312

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis and Inadequate Response/Intolerance to One Prior Tumor Necrosis Factor Inhibitor Through 1 Year of the SOLSTICE Study
Abstract Number: 1840

Efficacy and Safety of HR091506 Extended-Release Tablets Versus Febuxostat in Patients With Gout and Hyperuricemia: A Multicenter, Randomized, Double-Blind, Active-Controlled Phase 3 Trial
Abstract Number: 0218

Efficacy and Safety of IL-6 Inhibitors in Systemic Sclerosis: A Systematic Review and Meta-Analysis
Abstract Number: 2106

Efficacy and safety of Induction and tapering Therapy with Tofacitinib and Glucocorticoid in patients with Polymyalgia Rheumatica (ITTG PMR): An open-label randomized controlled trial
Abstract Number: 2107

Efficacy and Safety of Inebilizumab for the Treatment of IgG4-RD Across Age Subgroups: Analysis from the Open-label Period of the MITIGATE Trial
Abstract Number: 1129

Efficacy and Safety of Inebilizumab in Newly Diagnosed and Recurrent IgG4-RD Patients: Results From the Open-Label Period of the MITIGATE Study
Abstract Number: 0449

Efficacy and Safety of Janus Kinase Inhibitors in Rheumatoid Arthritis-Associated Interstitial Lung Disease: Potential Utility of Longitudinal Lung Ultrasound Assessment Using a Pleural Scale
Abstract Number: 1617

Efficacy and Safety of Nerandomilast in Patients with Autoimmune-Interstitial Lung Disease (ILD) and Progressive Pulmonary Fibrosis in Subgroups by Time Since ILD Diagnosis
Abstract Number: 0905

Efficacy and Safety of Nipocalimab in Participants with Idiopathic Inflammatory Myopathies: Results from the Phase 2 SPIREA Trial through 52 Weeks
Abstract Number: 0199

Efficacy and safety of obinutuzumab in granulomatosis with polyangiitis and microscopic polyangiitis: a multicenter retrospective study
Abstract Number: 1217

Efficacy and safety of obinutuzumab β, a novel glycoengineered type II anti-CD20 antibody, in patients with active systemic lupus erythematosus: results from a multicenter, randomized, double-blind, placebo-controlled phase 2 trial
Abstract Number: 2396

Efficacy and Safety of Ozoralizumab Plus Methotrexate in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract Number: 2397

Efficacy and Safety of Probiotics as an Adjunct to Standard Therapy in Active Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract Number: 1130

Efficacy and Safety of Selective Phosphodiesterase-4 Inhibitors for Oral Ulcers in Behçet’s Disease: A Meta-analysis of Randomized Trials
Abstract Number: 0874

Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
Abstract Number: 0981

Efficacy and Safety of Sotatercept in Patients with Pulmonary Arterial Hypertension (PAH) Associated with CTD: A Pooled Analysis of Three Phase 3 Trials
Abstract Number: 2647

Efficacy and safety of SSGJ-613 for acute gout flares in participants initiating urate-lowering therapy: a phase 2, randomized, open-label, multicenter, active-controlled trial
Abstract Number: 1505

Efficacy and Safety of Subcutaneous Ustekinumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis: Results of the Open-label, Phase 3 PSUMMIT-Jr Study Through Week 52
Abstract Number: 1377

Efficacy and Safety of Targeted Immunomodulatory Monoclonal Antibodies in Primary Sjögren’s Syndrome: A Systematic Review and Meta-analysis
Abstract Number: 0359

Efficacy and Safety of Tildrakizumab in Anti-TNF-Naïve Patients With Active Psoriatic Arthritis: Week 52 Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Abstract Number: 2398

Efficacy and Safety of Upadacitinib Versus Adalimumab in Patients With Rheumatoid Arthritis Having Primary or Secondary Failure or Intolerance to a Tumor Necrosis Factor Inhibitor: Post Hoc Analysis of the SELECT-SWITCH Study
Abstract Number: 1175

Efficacy and safety outcomes of real-world off label anifrolumab use in CLE with or without concomitant SLE: a systematic literature review
Abstract Number: 2200

Efficacy of Anifrolumab Across Multiple Organ Systems in Patients with Moderate to Severe Systemic Lupus Erythematosus: A Post-Hoc Analysis of the Phase III AZALEA trial
Abstract Number: 2201

Efficacy of Anifrolumab Treatment in Improving Joint Outcomes: Pooled Data from Intravenous and Subcutaneous Phase 3 Trials
Abstract Number: 2293

Efficacy of Apremilast in Patients with Early Psoriatic Arthritis: A Post Hoc Pooled Analysis of Seven Clinical Trials
Abstract Number: 2693

Efficacy of Apremilast on Fingernail Bed Inflammation in Patients With Psoriatic Arthritis: Dynamic Contrast-Enhanced MRI Results From the Phase 4 MOSAIC Study
Abstract Number: 2564

Efficacy of Cryoneurolysis Before Primary Knee Arthroplasty on Early Outcomes : An Updated Systematic Review and Meta-Analysis
Abstract Number: 2202

Efficacy of enpatoran on arthritis outcomes in participants with SLE and active skin and joint involvement: a post-hoc analysis of Cohort B of the phase II WILLOW study
Abstract Number: 2294

Efficacy of Half-Dose Versus Standard-Dose Tofacitinib in Axial Spondyloarthritis: A Double-Blind, Parallel-Group, Non-Inferiority Randomized Controlled Trial
Abstract Number: 0422

Efficacy of intravenous immunoglobulins in Sjögren’s disease-associated painful sensory neuropathies: results from a multicenter double blind randomized controlled study
Abstract Number: 0360

Efficacy of Izokibep, a Novel IL-17A Inhibitor, in Patients With Active Psoriatic Arthritis: A Subgroup Analysis From a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study
Abstract Number: 1313

Efficacy of Izokibep, a Novel IL-17A Inhibitor, in Patients With Active Psoriatic Arthritis: Composite Measures of Disease Activity and Patient-Reported Outcomes From a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study
Abstract Number: 1593

Efficacy of Mesenchymal Stromal Cells in Anti-MDA5+ Dermatomyositis with ILD: A Single-Center Retrospective Study
Abstract Number: 2779

Efficacy of Tocilizumab in Non-Infectious Uveitis: A Quantitative Leakage Analysis Using Ultra-Widefield Fluorescein Angiography
Abstract Number: 0232

Efficacy, Safety, and Potential Role of Pyridostigmine in the Management of Gastrointestinal Dysmotility: A Systematic Review.
Abstract Number: 2590

Efficacy, Safety, Tolerability and Pharmacodynamic Effect of Orally Administered GLPG3667 in Adults with Dermatomyositis: the GALARISSO study
Abstract Number: 0904

Efgartigimod PH20 SC Reduces Total Immunoglobulin G and Myositis-Specific Autoantibodies in Adults With Active Idiopathic Inflammatory Myopathy: Phase 2 Data From ALKIVIA
Abstract Number: 1017

EGFR Associated Signaling Defines Early Profibrotic Activation of COL11A1⁺ Fibroblasts in Discoid Lupus Erythematosus
Abstract Number: 2495

Electronic Health Record Algorithms Have Lower Predictive Value in Black Juvenile Idiopathic Arthritis Patients and are More Affected by Exclusion criteria
Abstract Number: 0919

Elevated Indole Metabolism Associates with Progression to Rheumatoid Arthritis and Promotes Dendritic Cell-Mediated Th17 Responses
Abstract Number: 1506

Elevated Interferon Gene Signatures in Childhood-Onset Systemic Lupus Erythematosus: Investigating Relationships with Disease Features, Depressive Symptoms, and Executive Function
Abstract Number: 0811

Elevated Osteoarthritis Prevalence Precedes Myasthenia Gravis Diagnosis: A Propensity-Matched Retrospective Cohort Study
Abstract Number: 0219

Elevated Serum Neurofilament Light Chain in Systemic Sclerosis: Associations with Clinical Manifestations
Abstract Number: 0738

Emergence of Merkel Cell Carcinoma During Janus Kinase Inhibitor Therapy
Abstract Number: 1618

Emerging Efficacy and Safety of Mivocabtagene Autoleucel, a Fully Human CD19 CAR T-Cell Therapy, in Severe Autoimmune Rheumatic Diseases
Abstract Number: 1266

Employment Trajectories of Patients with Systemic lupus erythematosus (SLE) and Factors Driving Transitions Between States
Abstract Number: 2475

Empowering Rheumatology Nursing Education in India: Validation of Modified RAKE tool (m-RAKE) to Assess Knowledge of Rheumatoid Arthritis Among Nursing Professionals
Abstract Number: 0566

EMR1 (ADGRE1) As a Biomarker of IFN-gamma Activity for Evaluation and Monitoring of MAS / HLH
Abstract Number: 1154

Emulated Target Trial of Corticosteroid Pulses for Induction Therapy in ANCA-Associated Vasculitis
Abstract Number: 0678

Endothelial Cells-Mediated Immune Cell Infiltration Promotes Retroperitoneal Fibrosis: Interrogation of Mechanisms and Translational Potential
Abstract Number: 1952

Engineered DcR3-Fc Fusion Protein: A Robust Dual-Targeting Approach for TL1A and LIGHT in Autoimmune Diseases
Abstract Number: 0970

Engineering A Fully Non-Matched CD19/BCMA Universal CAR-T Product with AI-Designed NK-Biased Ligands for Autoimmune Diseases
Abstract Number: 2083

Engineering and Development of a Novel Bispecific Antibody Targeting IL-23 and TL1A
Abstract Number: 1077

Enhanced Fibrogenic Pathways Define Scleromyositis Within the Spectrum of ACR/EULAR Myositis Subsets
Abstract Number: 2061

Enhanced NMU-NMUR1 Signaling Promotes Hyper-responsive ILC2-Mediated Type 2 Immunity in IgG4-Related Disease
Abstract Number: 0533

Enhancing Reproductive Health Delivery in Rheumatology: Adaptations to the HOP-STEP Intervention
Abstract Number: 1917

Enhancing SLE Clinical Trial Efficiency With Prognostic Score Covariate Adjustment
Abstract Number: 0567

Enrollment Patterns for the Newly Launched Pediatric Vasculitis Patient-Powered Research Network
Abstract Number: 2010

Enthesitis-Predominant Spondyloarthritis: Clinical Characteristics, HLA-B27 Association, and Utility of Expanded Ultrasound Screening in a Real-World Tertiary Care Cohort
Abstract Number: 2062

Environmental Conditions Impact the Severity of Lung Involvement in Collagen Induced Arthritis
Abstract Number: 1314

Envudeucitinib (ESK-001) in moderate-to-severe plaque psoriasis: 24-week results from the randomized, double-blind, active comparator- and placebo-controlled, Phase 3 ONWARD1 and 2 studies
Abstract Number: 1987

Envudeucitinib, an allosteric TYK2 inhibitor, inhibits SLE-relevant type I IFN biomarkers in skin using spatial transcriptomics
Abstract Number: 2619

Eosinophilic Fasciitis: Experience at a tertiary care center and favorable response to tocilizumab in six refractory cases.
Abstract Number: 2427

Epicardial Adipose Tissue Thickness Is Increased in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Abstract Number: 1002

Epicutaneous Desensitization with Chromatin Is a Novel Therapeutic Approach for Systemic Lupus Erythematosus by Inducing Antigen-specific Immune Tolerance
Abstract Number: 2620

Epidemiological trends in coexisting Stroke with Systemic Connective Tissue Diseases in the United States, 1999-2025
Abstract Number: 2108

Epidemiology and Outcomes of IgG4-Related Disease in a Nationwide United States Cohort
Abstract Number: 0679

Epidemiology of adult-onset still’s disease in northern spain: a 24-year population-based study
Abstract Number: 2134

Epidemiology of ANCA-Associated Vasculitis (AAV) in a Multiethnic Tertiary Care Centre Cohort
Abstract Number: 0812

Epidemiology of Mortality Associated with Diabetes Mellitus and Rheumatoid Arthritis in the United States from 1999 to 2020
Abstract Number: 2807

Equivalent effectiveness but decreased persistence in patients switched to biosimilar infliximab: evidence from real world data
Abstract Number: 1218

Erythrocyte-bound C4d (EC4d) Declines after Initiation of Mechanistically Diverse SLE Therapies
Abstract Number: 0059

Escape from X-Chromosome Inactivation is Implicated in Females with Systemic Lupus Erythematosus as a Mechanism of Ribonucleoprotein Upregulation
Abstract Number: 0548

Escape RHEUM: Gamification of Complex Rheumatoid Arthritis Cases Targeted for Rheumatology Fellows
Abstract Number: 2361

ESSDAI and ESSPRI Subdomain Analysis of Telitacicept in Patients With Primary Sjögren Disease
Abstract Number: 1661

Establishing Quality Improvement and Research Priorities in a Pediatric Rheumatology Learning Health Network: A Community-Informed Delphi Process
Abstract Number: 1943

Establishment and Validation of a Mouse Model of ANCA Associated Vasculitis
Abstract Number: 2745

Estimated Economic Burden of Systemic Lupus Erythematosus (SLE) Across Seven Countries: A Multi-Country Cost-of-Illness Model
Abstract Number: 1551

Estimating Heritability of Pain Sensitization and its Genetic Correlations with Joint and Non-Joint Pain: The Framingham Heart Study
Abstract Number: 2746

Estimating the Epidemiology of Uncontrolled Gout Among Adult Populations in US-Health Claims Data
Abstract Number: 2747

Estimation and Projection of the Economic Burden of Systemic Lupus Erythematosus in Urban China
Abstract Number: 1930

Estrogen Imprints Neutrophil Fate Through Epigenetic Programming of Hematopoiesis Underlying Female-biased Autoimmunity
Abstract Number: 0656

Ethnic Differences in Antisynthetase Syndrome: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” project database
Abstract Number: 2621

Etiology-Stratified Outcomes in Adult Hemophagocytic Lymphohistiocytosis: A Retrospective ICU Cohort Study Using MIMIC-IV
Abstract Number: 0757

EULAR Recommendations for the Use of Imaging in the Diagnosis and Management of Spondyloarthritis in Clinical Practice – 2025 Update
Abstract Number: 1782

European Practices for Screening and Follow-up of Mixed Connective Tissue Disease: A Cross-Sectional Survey of Clinicians from the European Federation of Internal Medicine and ERN ReCONNET
Abstract Number: 1507

Evaluating Associations between Diffusion Tensor Imaging Metrics and Cognitive Function in Youth with Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 0200

Evaluating Caregiver Burden in ANCA-Associated Vasculitis
Abstract Number: 0766

Evaluating Demographic Variability in AI-Generated Rheumatology Diagnostic and Referral Recommendations
Abstract Number: 0568

Evaluating Safety of Nonsteroidal Anti-inflammatory Drugs Across Subtypes of Pediatric Inflammatory Bowel Disease
Abstract Number: 0549

Evaluating the Impact of an eConsult-Informed ECHO Colorado Rheumatology Series for Primary Care Providers
Abstract Number: 0635

Evaluating the Long-Term Impacts of an Exercise Program on Pain and Function in Knee Osteoarthritis Patients
Abstract Number: 1723

Evaluating the Real-World Impact of a Digital Patient Management Platform for Patients with Axial Spondyloarthritis in an NHS Rheumatology Service: Interim Results from a Service Evaluation Study
Abstract Number: 1552

Evaluating the Risk of Ocular Pain in Patients with Complement-Related Disorders After Cataract Surgery
Abstract Number: 2748

Evaluating Time-To-Diagnosis For Patients With Systemic Lupus Erythematosus (SLE) Patients in the Research Accelerated by You (RAY®) Lupus Registry
Abstract Number: 2879

Evaluation of the Modified Berlin Algorithm for Diagnosing Axial SpA in Patients with Chronic Back Pain: Data from the SPondyloArthritis Caught Early (SPACE) Cohort
Abstract Number: 0550

Evaluation of a Health Equity Check-In Tool on an Inpatient Pediatric Rheumatology/Nephrology Team
Abstract Number: 1440

Evaluation of a screening strategy for interstitial lung disease in rheumatoid arthritis
Abstract Number: 1441

Evaluation of Cardiovascular Risk Assessment and Treatment in Rheumatoid Arthritis in a Large Health System -Lessons Learned and Opportunities for Improvement
Abstract Number: 1485

Evaluation of ChatGPT and OpenEvidence in Simulated IgG4-Related Disease Clinical Scenarios: Differences in Expert and Trainee Assessment
Abstract Number: 0233

Evaluation of decreased flow in the ulnar artery by ultrasound and the association with vascular complications in patients with systemic sclerosis
Abstract Number: 1652

Evaluation of DISSOLVE I/II Stopping Rules for Nanoencapsulated Sirolimus Plus Pegadricase (NASP) in Patients (pts) With Uncontrolled Gout
Abstract Number: 2428

Evaluation of Medication Adherence and Patient Satisfaction Over Time between Clustered Groups of Patients with Rheumatoid Arthritis
Abstract Number: 2465

Evaluation of Mood Changes Under TNF inhibitors in Chronic Inflammatory Rheumatic Diseases
Abstract Number: 2622

Evaluation of Outcomes Based on Early Versus Delayed Ureterolysis in Patients with Idiopathic Retroperitoneal Fibrosis
Abstract Number: 1912

Evaluation of Resource Utilization in a Rheumatology-Based Social Determinants of Health Screening and Navigation Program
Abstract Number: 1219

Evaluation of target exposure achievement for baseline MMF dose in the first 21 patients enrolled in the Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) study.
Abstract Number: 0310

Evaluation of the Clinical Frailty Scale in Systemic Lupus Erythematosus
Abstract Number: 1378

Evaluation of the Ianalumab Treatment Effects on Parotid and Submandibular Glands of Patients with Sjögren’s Disease by Multimodal Ultrasound: Results from a Phase 2 Mechanistic Study
Abstract Number: 0636

Evidence of a Dose-Response Relationship in a Phase 2b Study of a Fixed-Dose Combination of Apocynin and Paeonol in Knee OA Patients With Moderate to Severe Pain and Nociplastic Pain Features
Abstract Number: 1861

Evidence of the Dual Mechanism of Action of Ianalumab in the Circulation and Salivary Gland Tissue of Patients with Sjögren’s Disease: Results from a Phase 2 Mechanistic Study
Abstract Number: 0862

Evidence on the Clinical Validity of the 2023 ACR/EULAR Antiphospholipid Syndrome Criteria in a Longitudinal Lupus Cohort
Abstract Number: 0234

Evidence-based predictors of systemic sclerosis-interstitial lung disease patients: the EUSTAR-PPFstudy (CP number 148)
Abstract Number: 2749

Evolving Temporal Trends and Disparities in Rheumatoid Arthritis-Associated Cardiovascular Mortality Among Adults Aged ≥25 Years in the United States, 1999-2025: A CDC WONDER Analysis
Abstract Number: 2249

Evolving Temporal Trends and Disparities in Systemic Lupus Erythematosus-Associated Mortality Among U.S. Adults Aged ≥55 Years, 1999-2025: A CDC WONDER Analysis
Abstract Number: 2838

Ex vivo gene editing strategies for VEXAS syndrome
Abstract Number: 2829

Ex Vivo Immune-Protein Profiling Supports First-Line JAK versus TNF Inhibitor Selection in biologic- and targeted synthetic DMARD-naïve Rheumatoid Arthritis patients
Abstract Number: 2522

Examining differences in symptoms and treatment preference, an exploration of the Research Accelerated by You (RAY) Lupus Disease Registry
Abstract Number: 2496

Examining the Risk of Pediatric Uveitis Relapse After Discontinuation of Long-Term Systemic Immunosuppressive Therapy in a Retrospective Cohort
Abstract Number: 1131

Exercise Practices Among Patients with Takayasu’s Arteritis
Abstract Number: 1532

Exercise Preferences and Physical Activity Guideline Adherence Among People with Systemic Lupus Erythematosus
Abstract Number: 2885

Expanding genetic risk scores for rheumatoid arthritis-associated interstitial lung disease with novel risk variants
Abstract Number: 2623

Expanding the Clinical Significance of anti-Mi2 Antibodies: Real-world data from a single center
Abstract Number: 2949

Expansion of access to rheumatology care for rural veterans: Evaluation of the National Tele-rheumatology Program (NTRP) over its first two years using the RE-AIM framework
Abstract Number: 0595

Expected Benefit Thresholds for Vagus Nerve Stimulation in Rheumatoid Arthritis: A Patient Preference Survey
Abstract Number: 0657

Exploratory study on the effects of GLP-1 RA on Inclusion Body Myositis: A multicenter retrospective study
Abstract Number: 1220

Exploratory Urinary Biomarkers from an Open-Label Phase 1/2 Study of Rapcabtagene Autoleucel (YTB323) Suggest Reduced Intrarenal Inflammation in Severe Refractory Systemic Lupus Erythematosus
Abstract Number: 0569

Exploring Drivers of Clinical Non-Response in Youth with Axial Spondyloarthritis
Abstract Number: 1132

Exploring Heterogeneity in the Response Rates for Clinical Trials in Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Abstract Number: 2456

Exploring High-Risk Rheumatology Patients’ Perspectives on Preventive Sexual and Reproductive Health: A Qualitative Study
Abstract Number: 1706

Exploring Social Disadvantage and Resilience in Juvenile Idiopathic Arthritis: A Qualitative Study Using a Socioecological Framework
Abstract Number: 2476

Exploring the Care Provided by Adult Rheumatologists to Pediatric Patients
Abstract Number: 0386

Exploring the Relationship Between Meteorological Factors and Psoriatic Arthritis Disease Activity: Results from a Longitudinal Cohort Study
Abstract Number: 1745

Exploring the Risk of Ocular Adverse Events Associated with Janus Kinase Inhibitors: Analysis of the FDA Adverse Event Reporting System (FAERS)
Abstract Number: 2916

Exploring the Role of CD40/CD40L Pathway in Myositis and Its Targeting with a Novel Centyrin CD40-siRNA Therapeutic
Abstract Number: 1018

Expression of Response Gene to Complement-32 is Upregulated in Kidney Biopsies of Patients with Lupus Nephritis and Correlates with the Activity and Chronicity index
Abstract Number: 2011

EXTL3 Mutation Promotes Pathological Ossification in a Chronic Inflammatory Context in Ankylosing Spondylitis
Abstract Number: 2399

Extracellular matrix biomarkers reveal differential effects of anti-inflammatory therapies on tissue destruction and fibrogenesis across immune-mediated disease
Abstract Number: 1988

Extracellular Vesicles as Potential Biomarkers for Disease Activity and Monitoring in Lupus Nephritis
Abstract Number: 0845

Extracorporeal Shock Wave Therapy vs Local Corticosteroid Injection for Carpal Tunnel Syndrome: An Updated Systematic Review and Meta-analysis
Abstract Number: 1379

Extraglandular manifestations in primary Sjögren’s syndrome
Abstract Number: 1998

Extramedullary Erythroblasts Amplify Type I Interferon Responses Through DNA Scavenging in Lupus
Abstract Number: 0311

Extrarenal symptoms associate with fulfillment of fibromyalgia diagnostic criteria in the SLE AMP AIM cohort
Abstract Number: 2497

Extremely High Maternal Anti-Ro/La Antibody Titers Predict Non-Cardiac Neonatal Lupus Erythematosus Manifestations